Abstract
Although primary cytoreductive surgery for epithelial ovarian cancer is well accepted as the cornerstone of initial management, the benefits of cytoreductive surgery for patients with recurrent ovarian cancer remains unclear. Furthermore, no consensus has been reached concerning treatment strategies for recurrent epithelial ovarian cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
